Monopar Therapeutics (MNPR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $100.00 price target on the stock.
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16 [Seeking Alpha]
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.